The purpose of this trial is to evaluate the safety and indicators of efficacy of up to 4
doses of orally administered dabigatran etexilate, administered twice daily, compared to
placebo when given in addition to dual antiplatelet treatment in patients with an index
event (MI) at high risk for new ischaemic cardiovascular events.
Inclusion criteria Patients with acute coronary syndromes with at least one additional
risk factor for cardiovascular complications.
1. Long term treatment with any other oral anticoagulant
2. Severe/disabling stroke within last 6 months
3. Conditions associated with increased bleeding risk
4. Anaemia or thrombocytopenia
5. Severe renal impairment
6. Liver disease
7. Positive pregnancy test